ATS 2020 Advance Program

2:15 NAEPP EPR-4 Working Group: Update A.E. Dixon, MD, ATSF, Burlington, VT 2:35 Management of Severe Asthma: Recommendations From the ERS/ATS Guideline Committee F. Holguin, MD, MPH, Aurora, CO 2:55 Management of Mild Asthma: Update From GINA H.K. Reddel, MBBS, PhD, Glebe, Australia 3:15 An Unmet Need: Non-Eosinophilic Asthma M. Castro, MD, MPH, Kansas City, KS 3:35 Do Guidelines Make a Difference in the Treatment of Severe Asthma? F.D. Martinez, MD, Tucson, AZ 3:55 Panel Discussion: Q/A, Known, Unknowns, and Unknown Unknowns, and Next Steps N. Lugogo, MD, Ann Arbor, MI CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM A89 BACTERIOPHAGE THERAPY OF COMPLEX PULMONARY INFECTIONS Assemblies on Pulmonary Infections and Tuberculosis; Pediatrics 2:15 p.m. - 4:15 p.m. Target Audience Clinicians and Physician-Scientists interested in the recent developments using bacteriophage as therapy in complex pulmonary infections Objectives At the conclusion of this session, the participant will be able to: • describe the lifecycle of bacteriophage and how it might be used to help control infection; • identify the major challenges for successful phage therapy including patient selection, regulatory barriers, phage selection and measures of successful therapy; • describe current successes and failures of clinical phage therapy and how these might inform future phage therapy investigations. Bacteriophage therapy is now used on a compassionate need basis at several institutions for patients with highly resistant microbial communities that no longer responding to standard therapy. Furthermore, clinical trials are being planned in North America and Europe that are designed to answer the challenges of patient selection, phage cocktail design, dosing schedule, and measures of efficacy. This symposium is designed to provide the basic information to health care providers of 1) how the therapy works, 2) potential risks and challenges affecting efficacy, 3) early patient experience, 4) how the therapy might fit into current evaluation and therapeutic strategies. Chairing: D.J. Conrad, MD, La Jolla, CA L. Caverly, BA, MD, Ann Arbor, MI 2:15 Phage Therapy: Clinical Perspectives and Basic Phage Biology L. Caverly, BA, MD, Ann Arbor, MI 2:25 Challenges of Bacteriophage Therapy from the Perspective of a Phage Biologist A. Segall, PhD, San Diego, CA 2:50 Early Clinical Experience in Targeted Phage Therapy in Complex Pulmonary Infections J.L. Koff, MD, New Haven, CT 3:15 The Challenges of Bacteriophage Therapy of Mycobacterial Disease G. Hatfull, PhD, Pittsburgh, PA 3:40 The Integrated Multi-Omic Assessment of Complex Pulmonary Infections Using Viromic, Metagenomic Data: Implications for for Phage Therapy F. Rohwer, PhD, San Diego, CA 4:05 A Clinical Perspective on Patient Selection, Outcome Safety and Efficacy Assessments, Regulatory Issues and Ethical Considerations D.J. Conrad, MD, La Jolla, CA ATS 2020 • Philadelphia, PA 60 SUNDAY • MAY 17